MA56205A - Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation - Google Patents

Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation

Info

Publication number
MA56205A
MA56205A MA056205A MA56205A MA56205A MA 56205 A MA56205 A MA 56205A MA 056205 A MA056205 A MA 056205A MA 56205 A MA56205 A MA 56205A MA 56205 A MA56205 A MA 56205A
Authority
MA
Morocco
Prior art keywords
pcrv
antibodies
bind
compositions
methods
Prior art date
Application number
MA056205A
Other languages
English (en)
Inventor
Alida Coppi
Christos Kyratsous
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA56205A publication Critical patent/MA56205A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA056205A 2019-06-11 2020-06-10 Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation MA56205A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962860146P 2019-06-11 2019-06-11

Publications (1)

Publication Number Publication Date
MA56205A true MA56205A (fr) 2022-04-20

Family

ID=71948699

Family Applications (2)

Application Number Title Priority Date Filing Date
MA056205A MA56205A (fr) 2019-06-11 2020-06-10 Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation
MA54975A MA54975B1 (fr) 2019-06-11 2020-06-10 Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA54975A MA54975B1 (fr) 2019-06-11 2020-06-10 Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation

Country Status (17)

Country Link
US (2) US11655286B2 (fr)
EP (1) EP3983015A1 (fr)
JP (1) JP2022536469A (fr)
KR (1) KR20220019755A (fr)
CN (1) CN113966343A (fr)
AU (1) AU2020292283A1 (fr)
BR (1) BR112021023335A2 (fr)
CA (1) CA3140075A1 (fr)
CL (4) CL2021003215A1 (fr)
CO (1) CO2021015254A2 (fr)
EA (1) EA202192810A1 (fr)
IL (1) IL288727A (fr)
MA (2) MA56205A (fr)
MX (1) MX2021015156A (fr)
PH (1) PH12021552903A1 (fr)
SG (1) SG11202112462RA (fr)
WO (1) WO2020252029A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10597439B2 (en) 2011-11-07 2020-03-24 Medimmune Limited Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
FR3114970B1 (fr) 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
CN114404614B (zh) * 2022-01-28 2024-04-23 上海交通大学 一种靶向铜绿假单胞菌的免疫脂质体及其制备方法和应用
CN117222740A (zh) * 2022-06-07 2023-12-12 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗
WO2024206669A2 (fr) * 2023-03-29 2024-10-03 Virtuoso Binco, Inc. Anticorps pour cibler cd47 et b7h3 et leurs méthodes d'utilisation
EP4735478A1 (fr) 2023-06-28 2026-05-06 Universität zu Köln Neutralisation d'anticorps monoclonaux humains contre p. aeruginosa
CN118530352B (zh) * 2024-05-11 2025-03-25 重庆原伦生物科技有限公司 一种特异性识别铜绿假单胞菌PcrV的抗体及其应用
CN118440191B (zh) * 2024-05-11 2025-06-10 重庆原伦生物科技有限公司 一种抗铜绿假单胞菌PcrV抗体的制备及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
EP1135415B1 (fr) 1998-12-01 2010-08-11 Facet Biotech Corporation Anticorps anti-interferon gamma humanises
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1353688B1 (fr) 2001-01-26 2006-12-06 MCW Research Foundation, Inc. Procede et compositions d'immunisation avec l'antigene v de i pseudomonas /i
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (fr) 2004-04-20 2005-11-03 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
WO2006044962A1 (fr) 2004-10-19 2006-04-27 Regeneron Pharmaceuticals, Inc. Methode de production d'un animal homozygote pour une modification genetique
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
SG186017A1 (en) * 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
AU2009203426C1 (en) 2008-01-10 2012-05-31 Shionogi & Co., Ltd. Antibody directed against PcrV
EA017288B1 (ru) 2008-01-11 2012-11-30 Эли Лилли Энд Компани (E)-N-{3-[1-(8-ФТОР-11Н-10-ОКСА-1-АЗАДИБЕНЗО[a,d]ЦИКЛОГЕПТЕН-5-ИЛИДЕН)ПРОПИЛ]ФЕНИЛ}МЕТАНСУЛЬФОНАМИД В КАЧЕСТВЕ МОДУЛЯТОРА РЕЦЕПТОРОВ ГЛЮКОКОРТИКОИДОВ ДЛЯ ЛЕЧЕНИЯ РЕВМАТИЗМА
DK2407537T6 (en) 2009-03-11 2015-07-27 Shionogi & Co PcrV HUMANIZED ANTIBODY WITH ACTIVITY ANTIPSEUDOMONAL
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
WO2012122533A2 (fr) 2011-03-10 2012-09-13 The University Of Chicago Compositions et procédés liés à des anticorps contre les protéines staphylococciques isda ou isdb
HRP20151188T4 (hr) 2010-02-08 2021-10-01 Regeneron Pharmaceuticals, Inc. Miš sa zajedničkim lakim lancem
US10597439B2 (en) * 2011-11-07 2020-03-24 Medimmune Limited Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
EP2793944B1 (fr) 2011-12-23 2025-10-08 Nicholas B. Lydon Immunoglobulines et variants dirigés contre des microbes pathogènes
JP2015535005A (ja) * 2012-11-06 2015-12-07 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
WO2017095744A1 (fr) * 2015-11-30 2017-06-08 Medimmune, Llc Procédé de prévention ou de traitement d'une pneumonie nosocomiale
GB201602156D0 (en) 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
BR112020004977A2 (pt) 2017-09-29 2020-10-06 Regeneron Pharmaceuticals, Inc. moléculas de ligação de antígenos biespecíficas que ligam antígeno alvo de staphyocococcus e componente de complemento e usos dos mesmos

Also Published As

Publication number Publication date
CL2023003694A1 (es) 2024-06-14
CA3140075A1 (fr) 2020-12-17
IL288727A (en) 2022-02-01
WO2020252029A1 (fr) 2020-12-17
US11655286B2 (en) 2023-05-23
CO2021015254A2 (es) 2021-11-19
CN113966343A (zh) 2022-01-21
MX2021015156A (es) 2022-01-18
EP3983015A1 (fr) 2022-04-20
MA54975B1 (fr) 2023-08-31
SG11202112462RA (en) 2021-12-30
CL2023003695A1 (es) 2024-06-14
AU2020292283A1 (en) 2021-12-23
US20200392210A1 (en) 2020-12-17
CL2023003696A1 (es) 2024-06-14
KR20220019755A (ko) 2022-02-17
CL2021003215A1 (es) 2022-09-30
PH12021552903A1 (en) 2022-04-04
EA202192810A1 (ru) 2022-03-05
US20230322907A1 (en) 2023-10-12
JP2022536469A (ja) 2022-08-17
BR112021023335A2 (pt) 2022-01-04
US12552856B2 (en) 2026-02-17
MA54975A1 (fr) 2022-05-31

Similar Documents

Publication Publication Date Title
EP3917564A4 (fr) Anticorps anti-claudine 18 et leurs méthodes d'utilisation
EP3826612A4 (fr) Nouveaux anticorps monoclonaux spécifiques à cldn 18.2 et leurs méthodes d'utilisation
EP3852805A4 (fr) Anticorps anti-lilrb2 et leurs méthodes d'utilisation
EP3801551A4 (fr) Compositions comprenant des composés bisfluoroalkyl-1,4-benzodiazépinone et des agents immunothérapeutiques et leurs méthodes d'utilisation
EP3621641A4 (fr) Domaines de liaison anti-cd3 et anticorps les comprenant, leurs procédés de génération et d'utilisation
MA52459A (fr) Anticorps se liant spécifiquement à pd-1 et leurs méthodes d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
EP3959318A4 (fr) Compositions d'oligonucléotides et leurs méthodes d'utilisation
EP3645742A4 (fr) Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation
MA50354A (fr) Anticorps ciblant le cd137 et leurs méthodes d'utilisation
EP3464346A4 (fr) Anticorps, composition et kits les comprenant et leurs procédés d'utilisation
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
EP3953385A4 (fr) Anticorps cd19 et leurs procédés d'utilisation
EP3684369A4 (fr) Compositions d'anticorps a33 et leurs méthodes d'utilisation en radioimmunothérapie
EP4004051A4 (fr) Anticorps immunomodulateurs et leurs méthodes d'utilisation
EP3731867A4 (fr) Anticorps anti-lrp5/6 et leurs procédés d'utilisation
EP3773718A4 (fr) Compositions et procédés comprenant des anticorps anti-nrp2
MA71328A (fr) Anticorps anti-ror1 et conjugués d'anticorps, compositions comprenant des anticorps anti-ror1 ou des conjugués d'anticorps, et méthodes de fabrication et d'utilisation d'anticorps anti-ror1 et de conjugués d'anticorps
MA53492A (fr) Anticorps anti-cd33 et leurs méthodes d'utilisation
MA51903A (fr) Formulations d'anticorps b7-h4
EP3823978A4 (fr) Compositions d'anticorps anti-fcrn
MA55750A (fr) Formulations d'anticorps stables et à faible viscosité et leurs utilisations
EP3955902A4 (fr) Compositions en aérosol comprenant des mitochondries et leurs méthodes d'utilisation
EP3790552A4 (fr) Compositions de combinaison comprenant des composés de bisfluoroalkyle-1,4-benzodiazépinone et leurs procédés d'utilisation
MA50958A (fr) Anticorps anti-apoc3 et leurs méthodes d'utilisation